Drug Profile
Larotinib - Sunshine Lake Pharma
Alternative Names: 14C - larotinib; Z 650Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Developer HEC Pharm; Sunshine Lake Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Oesophageal cancer
- No development reported Pancreatic cancer
- Discontinued Non-small cell lung cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Metastatic disease, Recurrent) in China (PO, Capsule)
- 13 Dec 2022 Sunshine Lake Pharma completes a phase I/II trial in Oesophageal cancer (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT03888092)
- 01 Oct 2021 Sunshine Lake Pharma plans a phase I ADME study (In Volunteers) (PO) in December 2021 (NCT05059743)